for people ages 18 years and up (full criteria)
at Clovis, California and other locations
study started
estimated completion



The purpose of this study is to determine the side effects of treatment of the combination of nivolumab and daratumumab in participants with relapsed/refractory multiple myeloma.

Official Title

Multiple Phase 1/2 Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic Malignancies


NOTE: Currently, this study is only open to nivolumab+daratumumab vs daratumumab monotherapy in multiple myeloma patients.


Non-Hodgkin's Lymphoma Hodgkin Lymphoma Multiple Myeloma Lymphoma Neoplasms, Plasma Cell Dexamethasone Nivolumab Ipilimumab Daratumumab Pomalidomide Lirilumab Nivolumab + Ipilimumab Nivolumab + Lirilumab Nivo + Dara + Pom + Dexa vs. Nivo + Dara Daratumumab vs. Nivolumab + Daratumumab


For people ages 18 years and up

For more information regarding BMS clinical trial participation, please visit

Inclusion Criteria:

  • Have received at least 3 prior lines of therapy, including a proteasome inhibitor [PI] and an immunomodulatory agent [IMiD] OR have disease that is double refractory to a PI and IMiD
  • More than 12 weeks post-transplant of your own blood forming stem cells (autologous transplant)
  • Have detectable disease measured by a specific protein in your blood and/or urine
  • Must consent to bone marrow aspirate or biopsy.

Exclusion Criteria:

  • Solitary bone or extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia, or monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), primary amyloidosis, Waldenstrom's macroglobulinemia, POEMS syndrome or active plasma cell leukemia
  • Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti CTLA 4, or anti-CD38 antibody, or allogeneic stem cell transplantation
  • Seropositive for human immunodeficiency virus (HIV), Hepatitis B surface antigen or Hepatitis C antibody positive (except if HCV-RNA negative), or history of active chronic hepatitis B or C
  • History of central nervous system involvement or symptoms suggestive of central nervous system involvement by multiple myeloma

Other protocol defined inclusion/exclusion criteria could apply


  • Ucsf Fresno
    Clovis California 93611 United States
  • Division Of Hematology & Oncology Ctr. For Health Sciences
    Los Angeles California 90095 United States


in progress, not accepting new patients
Start Date
Completion Date
Bristol-Myers Squibb
BMS Clinical Trial Information BMS Clinical Trial Patient Recruiting FDA Safety Alerts and Recalls
Phase 1/2
Study Type
Last Updated